Generic Name and Formulations:
Tetanus and diphtheria toxoids; aluminum adsorbed; susp for IM inj; preservative-free.
Sanofi Pasteur, Inc.
Indications for TENIVAC:
Tetanus and diphtheria immunization in patients >7yrs.
Adults and Children:
<7yrs: not established. >7yrs: Give IM in deltoid muscle. Previously unvaccinated: three 0.5mL doses, administer first two doses 2 months apart and then third dose 6–8 months after second dose. Routine booster: give at 11–12yrs of age and every 10 years thereafter. Diphtheria and tetanus prophylaxis: see full labeling.
Anaphylaxis associated with a previous dose.
Guillain-Barre syndrome within 6 weeks of previous tetanus toxoid vaccine. Previous Arthus-type hypersensitivity reaction: not recommended until ≥10yrs after prior dose of tetanus toxoid-containing vaccine. Immunodeficiency. Have epinephrine (1:1000) available. Latex allergy (syringe tip cap). Pregnancy (Cat.C). Nursing mothers.
Concomitant tetanus immune globulin (human): inject at separate site with separate needle and syringe if passive protection required. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.
Injection site reactions (eg, pain, redness, swelling), headache, malaise, muscle weakness, joint pain.
Single-dose vials (0.5mL)—10
Single-dose prefilled syringe (0.5mL)—10
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|